BioCentury | Jan 27, 2017
Clinical News

Tedopi: Ph III Atalante 1 ongoing

...An IDMC recommended continuation of the open-label, international Phase III Atalante 1 trial comparing subcutaneous Tedopi...
...vs. IV docetaxel or IV pemetrexed in about 500 HLA-A2 positive patients. Patients will receive Tedopi...
...OSE Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Rafa Laboratories Ltd. , Jerusalem, Israel Product: Tedopi (OSE 2101...
BioCentury | Mar 14, 2016
Company News

Effimune, OSE Pharma deal

...companies. OSE’s Tedopi is in Phase III testing to treat non-small cell lung cancer (NSCLC). Tedopi...
BioCentury | Feb 1, 2016
Clinical News

Tedopi: Phase III started

...Orphan Synergy Europe began the open-label, international Phase III ATALANTE 1 trial to compare subcutaneous Tedopi...
...vs. IV docetaxel or IV pemetrexed in about 500 HLA-A2 positive patients. Patients will receive Tedopi...
...Euronext:OSE), Paris, France Product: Tedopi ( OSE 2101 ) (formerly EP2101 , Texopi , IDM-2101 , EP-2101...
BioCentury | Sep 21, 2015
Clinical News

Tedopi: Phase IIb data

...HLA-A2-positive stage IIIB/IV NSCLC patients with brain metastases in a Phase IIb trial showed that Tedopi...
...to a median overall survival (OS) of 13.75 months. In 5 of the 6 patients, Tedopi...
...Euronext:OSE), Paris, France Product: Tedopi ( OSE 2101 ) (formerly EP2101 , Texopi , IDM-2101 , EP-2101...
BioCentury | Jun 8, 2015
Company News

OSE Pharma, Rafa deal

...Orphan Synergy Europe granted Rafa exclusive rights to develop and commercialize Tedopi in Israel. Rafa will...
...in Israel. OSE declined to provide further financial terms, and Rafa could not be reached. Tedopi...
BioCentury | Mar 27, 2015
Financial News

OSE Pharma raises EUR 21.1M in IPO

...financial advisor. Next half, OSE plans to start a Phase III trial of lead candidate Tedopi...
...lung cancer (NSCLC) in patients who express the HLA-A2 receptor and have failed first-line therapy. Tedopi...
BioCentury | Sep 19, 2014
Financial News

OSE Pharma plans IPO on Euronext Paris

...IPO on Euronext Paris by year end to fund clinical trials of its immunotherapy Tedopi. Tedopi...
...as a second-line treatment is slated to start in 2H15 in the U.S. and Europe. Tedopi...
...who express the HLA-A2 receptor. The company plans to begin a Phase II trial of Tedopi...
BioCentury | Feb 25, 2013
Clinical News

OSE 2101 regulatory update

...Orphan Synergy Europe-Pharma said FDA granted Orphan Drug designation for OSE 2101 to treat non-small cell lung...
...to treat non-small cell lung cancer (NSCLC) in HLA-A2-positive patients. A Phase II trial of OSE 2101...
...Switzerland Orphan Synergy Europe-Pharma S.A. , Paris, France Product: OSE 2101 (formerly EP-2101 , IDM-2101 , EP2101...
BioCentury | Jul 16, 2012
Company News

Orphan Synergy Europe-Pharma cancer news

...rights and European commercialization rights from EU Synergy Epitopes S.A. (Geneva, Switzerland) to EP2101 ( EP-2101...
...In 2009, IDM was acquired by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan), which out-licensed EP2101...
...2011 to Biotech Synergy (San Diego, Calif.), which Loria founded. EU Synergy Epitopes later acquired EP2101...
BioCentury | Jul 14, 2012
Company News

OSE-Pharma debuts to resume development of EP2101

...San Diego-based Epimmune Inc. OSE-Pharma acquired worldwide development rights and European commercialization rights to EP2101 (EP-2101...
...Pharma Inc. In 2009, IDM was acquired by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), which out-licensed EP2101...
Items per page:
1 - 10 of 35